We are constantly seeking participants for a number of studies. Please apply to any studies for which you may qualify, or call us at (417) 883-7889 for more information!
As part of a nationwide study, Clinvest and Missouri State University are working to improve the way in which we evaluate the impact of migraine on patient’s lives. We are looking for participants who can help shed some insight into the important factors patients use to evaluate their own response to treatment. This online survey will ask questions to find our more information about your migraines, treatment, and what you feel are the most important components to feeling better. It should take no longer than 90 minutes to complete the survey requirements.The end result of this project will be a preliminary questionnaire that will help patients and clinicians evaluate the impact of migraine on their lives.
This study consists of 5 in-person visits and 1 phone call over 16 weeks. Qualified people who report 8-20 headaches per month will be randomized to use non-invasive vagus nerve stimulation delivered through an investigational device 3 times a day during a 12-week treatment phase. Your first appointment would last approximately 2 hours. If you qualify and choose to volunteer, we would provide the study device and all study-related procedures at no cost to you. You would be asked to use an electronic diary to answer daily questions about your headaches for the entire duration of the study. You would also be asked to fill out more detailed questionnaires during the appointments. Compensation will be provided for your time and travel.
Qualified subjects will be randomized to take a pill every other day for 12 weeks, either active or placebo followed by an additional 12 weeks of receiving active product. This study has 12 visits and is 30 weeks in duration. Your first appointment would last approximately 2 hours. If you qualify and choose to volunteer, we would provide an investigational study pill and all study-related procedures at no cost to you (including basic study-related physical exams, bloodwork, ECG’s, and urine drug/pregnancy tests). You would be asked to use a handheld electronic diary to answer daily questions about your headaches for the entire duration of the study. You would also be asked to fill out more detailed questionnaires during the appointments. Compensation will be provided for your time and travel.
The purpose of this study is to determine the benefit of taking 300mg of an investigational drug compared to the currently approved 150mg dose for patients with Ankylosing Spondylitis (AS). Qualifying volunteers would come to our office for approximately 19 visits over a 52-week period. Patients will be given 16 doses of the investigational drug during the course of the study.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of investigational medication for the Acute Treatment of Episodic Migraine in Adolescents. Qualified patients ages 12-17 will attend up to 3 visits and treat up to 2 migraines over 28 weeks with study medication.
This research study is to compare the duration, safety, and effectiveness of the investigational study medication (Fremanezumab) to placebo (an inactive look-alike). Qualified volunteers will be randomly assigned to receive study medication or placebo. Completion of the study would involve coming to our office for 7 appointments, over a 44-week period. Subjects will receive 3 doses of investigational product or placebo during the study.
The study is for subjects 18 and older. The study duration is up to 3 years. Subject will receive both oral study drug once daily and subcutaneous study drug every other week. Period 1 is 56 weeks and 13 site visits. Subject will have a site visit at week 56 and every 12 weeks thereafter.
The research study is available for participants 18 and older. The subject will take the study drug once daily. There are 13 office visits in Period 1. The study duration is up to 3 years. Subject will have a study visit at week 56 and every 12 weeks thereafter.